Hsa‐miR‐653 has been revealed to inhibit cancer progression in hepatocellular carcinoma, prostate cancer, breast cancer, papillary thyroid carcinoma, ovarian cancer, and gastric cancer,59, 60, 61, 62, 63, 64 while Liu et al. reported that miR‐653 enhances CRC progression by targeting circSETD3/KLF6 axis recently.65 This evidence concerns the gene KLF6 and hepatocellular carcinoma.